All the news

Three new methods using readily available clinical parameters can help predict who will develop hepatocellular carcinoma (HCC) after achieving sustained virological response to hepatitis C treatment, according to studies presented at the recent 2020 Digital ...

Three checkpoint inhibitor immunotherapy regimens show promise for people with hepatocellular carcinoma (HCC), the most common type of liver cancer, according to a set of late-breaking presentations last week at the 2020 Digital ...

People with HIV who were cured of hepatitis C were less likely than HIV-negative people to develop hepatocellular carcinoma (HCC – liver cancer) in the three-and-a-half years after completing hepatitis C treatment, Spanish ...

A healthy lifestyle, including smoking cessation, moderate drinking, a balanced diet, exercise and weight loss could dramatically reduce the growing burden of liver cancer and deaths due to liver disease, according to a study ...

People with liver cancer who achieved a sustained virological response (SVR) to direct-acting antiviral (DAA) therapy for hepatitis C saw a reduction in both liver-related and all-cause mortality over five years, according to ...

Direct-acting antiviral treatment for hepatitis C need not be delayed until the completion of treatment for hepatocellular carcinoma (HCC; liver cancer), but people with hepatitis C need to be warned of a ...